Intel stock extends gains after report of possible U.S. government stake
Director Jane Henderson of Akero Therapeutics, Inc. (NASDAQ:AKRO), a $3.84 billion market cap company, sold 3,000 shares of common stock on August 12, 2025, at a price of $47.457, for a total value of $142,371. The stock has shown remarkable strength with a 94% return over the past year, despite a recent 9% decline in the past week.
On the same day, Henderson also exercised options to acquire 3,000 shares of Akero Therapeutics common stock at a price of $7.009, for a total value of $21,027. Following these transactions, Henderson directly owns 9,398 shares of Akero Therapeutics. According to InvestingPro, the company maintains strong liquidity with a current ratio of 12.66 and shows low market correlation with a beta of -0.28.
The options exercised were vested and immediately exercisable. They expire on April 2, 2029. Want deeper insights into insider trading patterns and 10+ additional exclusive tips? Check out InvestingPro for comprehensive analysis.
In other recent news, Akero Therapeutics has garnered attention following the release of its clinical trial data and subsequent analyst reactions. Akero’s recent presentation at the European Association for the Study of the Liver (EASL) highlighted positive outcomes from a placebo-controlled study on F4 cirrhosis, with findings published in The New England Journal of Medicine. Analysts from Jefferies have maintained a Buy rating, emphasizing the robust data and projecting a market opportunity between $2 billion and $5 billion. Meanwhile, Citi adjusted Akero’s price target to $78 from $80, maintaining a Buy rating, following the release of Phase 2b SYMMETRY trial data that demonstrated positive effects on liver fibrosis metrics.
Morgan Stanley (NYSE:MS) reiterated its Overweight rating with an $84 price target, citing Akero’s strengthened competitive position after Novo Nordisk (NYSE:NVO) discontinued its MASH treatment development. TD Cowen initiated coverage with a Buy rating and a $76 price target, highlighting Akero’s FGF21 analog efruxifermin for its strong efficacy data and potential commercial success in treating MASH. Akero’s research and clinical data continue to drive analyst confidence, with potential acquisition interest noted due to the promising results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.